{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:56:27Z","timestamp":1791896187500,"version":"4.3.4"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Blocking the CD47 \u201cdon\u2019t eat me\u201d-signal on tumor cells with monoclonal antibodies or fusion proteins has shown limited clinical activity in hematologic malignancies and solid tumors thus far. Main side effects are associated with non-tumor targeted binding to CD47 particularly on blood cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We present here the generation and preclinical development of NILK-2401, a CEACAM5\u00d7CD47 bispecific antibody (BsAb) composed of a common heavy chain and two different light chains, one kappa and one lambda, determining specificity (so-called \u03ba\u03bb body format).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>NILK-2401 is a fully human BsAb binding the CEACAM5 N-terminal domain on tumor cells by its lambda light chain arm with an affinity of \u22484 nM and CD47 with its kappa chain arm with an intendedly low affinity of \u2248500 nM to enabling tumor-specific blockade of the CD47-SIRP\u03b1 interaction. For increased activity, NILK-2401 features a functional IgG1 Fc-part. NILK-2401 eliminates CEACAM5-positive tumor cell lines (3\/3 colorectal, 2\/2 gastric, 2\/2 lung) with EC<jats:sub>50<\/jats:sub> for antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity ranging from 0.38 to 25.84 nM and 0.04 to 0.25 nM, respectively. NILK-2401 binds neither CD47-positive\/CEACAM5-negative cell lines nor primary epithelial cells. No erythrophagocytosis or platelet activation is observed. Quantification of the pre-existing NILK-2401-reactive T-cell repertoire in the blood of 14 healthy donors with diverse HLA molecules shows a low immunogenic potential. <jats:italic>In vivo<\/jats:italic>, NILK-2401 significantly delayed tumor growth in a NOD-SCID colon cancer model and a syngeneic mouse model using human CD47\/human SIRP\u03b1 transgenic mice and prolonged survival. In cynomolgus monkeys, single doses of 0.5 and 20 mg\/kg were well tolerated; PK linked to anti-CD47 and Fc-binding seemed to be more than dose-proportional for C<jats:sub>max<\/jats:sub> and AUC<jats:sub>0-inf<\/jats:sub>. Data were validated in human FcRn TG32 mice. Combination of a CEACAM5-targeting T-cell engager (NILK-2301) with NILK-2401 can either boost NILK-2301 activity (Emax) up to 2.5-fold or allows reaching equal NILK-2301 activity at &amp;gt;600-fold (LS174T) to &amp;gt;3,000-fold (MKN-45) lower doses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>NILK-2401 combines promising preclinical activity with limited potential side effects due to the tumor-targeted blockade of CD47 and low immunogenicity and is planned to enter clinical testing.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1378813","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T05:01:20Z","timestamp":1713934880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 \u03ba\u03bb bispecific antibody"],"prefix":"10.3389","volume":"15","author":[{"given":"Anja","family":"Seckinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Buatois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Moine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Daubeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Chatel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliz\u00e9e","family":"Viandier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Rousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Masternak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Salgado-Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Mougin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Juan-B\u00e9geot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Poitevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coi.2016.02.006","article-title":"Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection","volume":"40","author":"Zhukovsky","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by hu5F9-G4 and rituximab in non-hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136607","article-title":"Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-human dose escalation study","volume":"136","author":"Patel","year":"2020","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1079","article-title":"Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding","volume":"19","author":"Puro","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic Malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2623","article-title":"Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRP\u03b1 inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors","volume":"39","author":"Champiat","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00271-4","article-title":"Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sezary syndrome: a multicentre, phase 1 study","volume":"8","author":"Querfeld","year":"2021","journal-title":"Lancet Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005517","article-title":"Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity","volume":"10","author":"Qu","year":"2022","journal-title":"J ImmunoTherapy Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13045-022-01385-2","article-title":"SIRP\u03b1-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47\/SIRP\u03b1 signal pathway via blocking the \u201cdon\u2019t eat me\u201d signal and activating the \u201ceat me\u201d signal","volume":"15","author":"Yu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1038\/s41598-023-32547-y","article-title":"HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models","volume":"13","author":"Ke","year":"2023","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/antib7010003","article-title":"Tumor-directed blockade of CD47 with bispecific antibodies induces adaptive antitumor immunity","volume":"7","author":"Dheilly","year":"2018","journal-title":"Antibodies (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/47.4.624","article-title":"Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful","volume":"47","author":"Duffy","year":"2001","journal-title":"Clin Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2644","article-title":"ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer","volume":"24","author":"Locker","year":"2006","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-013-9444-6","article-title":"Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis","volume":"32","author":"Beauchemin","year":"2013","journal-title":"Cancer Metastasis Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28384","article-title":"Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update","volume":"134","author":"Duffy","year":"2014","journal-title":"Int J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2006.08.008","article-title":"CEACAMs: their role in physiology and pathophysiology","volume":"18","author":"Kuespert","year":"2006","journal-title":"Curr Opin Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18632\/genesandcancer.v14","article-title":"CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens","volume":"14","author":"Thomas","year":"2023","journal-title":"Genes Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113636","article-title":"Release of carcinoembryonic antigen from human colon cancer cells by phosphatidylinositol-specific phospholipase C","volume":"82","author":"Sack","year":"1988","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.05.084","article-title":"Cleavage of carcinoembryonic antigen induces metastatic potential in colorectal carcinoma","volume":"333","author":"Yamamoto","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2005.03.028","article-title":"Evidence for CEA release from human colon cancer cells by an endogenous GPI-PLD enzyme","volume":"234","author":"Naghibalhossaini","year":"2006","journal-title":"Cancer Lett"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-011-1144-0","article-title":"Regulation of carcinoembryonic antigen release from colorectal cancer cells","volume":"39","author":"Pakdel","year":"2012","journal-title":"Mol Biol Rep"},{"key":"B31","article-title":"Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue","volume":"49","author":"Boucher","year":"1989","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1006\/scbi.1998.0119","article-title":"The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and Malignant tissues","volume":"9","author":"Hammarstrom","year":"1999","journal-title":"Semin Cancer Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2014.975660","article-title":"CEA\/CD3 bispecific antibody MEDI-565\/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas","volume":"6","author":"Oberst","year":"2014","journal-title":"MAbs"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1696","article-title":"A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors","volume":"22","author":"Bacac","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.18.622","article-title":"Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results","volume":"23","author":"Liersch","year":"2005","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.07.009","article-title":"Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas","volume":"15","author":"Pishvaian","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase I\/II trial of labetuzumab govitecan (Anti-CEACAM5\/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3002","article-title":"Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC)","volume":"35","author":"Tabernero","year":"2017","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody\u2013drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1038\/ncomms7113","article-title":"Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG","volume":"6","author":"Fischer","year":"2015","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1095","article-title":"Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia","volume":"17","author":"Buatois","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-280875","article-title":"Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential","volume":"116","author":"Delluc","year":"2010","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1096\/fj.10-173872","article-title":"Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors","volume":"25","author":"Delluc","year":"2011","journal-title":"FASEB J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12422","article-title":"Keyhole limpet haemocyanin \u2013 a model antigen for human immunotoxicological studies","volume":"78","author":"Swaminathan","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169171","article-title":"First-in-human (FIH) study of the fully-human kappa-lambda CD19\/CD47 bispecific antibody TG-1801 in patients (pts) with B-cell lymphoma","volume":"140","author":"Hawkes","year":"2022","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1739408","DOI":"10.1080\/19420862.2020.1739408","article-title":"Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors","volume":"12","author":"Hatterer","year":"2020","journal-title":"MAbs"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0707","article-title":"A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers","volume":"10","author":"Romano","year":"2022","journal-title":"J ImmunoTherapy Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.25234","article-title":"Immunogenicity of mAbs in non-human primates during nonclinical safety assessment","volume":"5","author":"van Meer","year":"2013","journal-title":"mAbs"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1193660","article-title":"Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies","volume":"8","author":"Avery","year":"2016","journal-title":"MAbs"},{"key":"B51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological Malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"biomark Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1062192","article-title":"A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells","volume":"7","author":"Piccione","year":"2015","journal-title":"MAbs"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1558698","article-title":"Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor\/CD19 association leading to impaired B-cell proliferation","volume":"11","author":"Hatterer","year":"2019","journal-title":"MAbs"},{"key":"B54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12951-020-0571-2","article-title":"Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential","volume":"18","author":"Ma","year":"2020","journal-title":"J Nanobiotechnology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.01.006","article-title":"A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC","volume":"29","author":"Du","year":"2021","journal-title":"Mol Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1741-7007-8-12","article-title":"Coevolution of activating and inhibitory receptors within mammalian carcinoembryonic antigen families","volume":"8","author":"Kammerer","year":"2010","journal-title":"BMC Biol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2003.03591.x","article-title":"Immunoreceptor tyrosine-based activation motif phosphorylation during engulfment of Neisseria gonorrhoeae by the neutrophil-restricted CEACAM3 (CD66d) receptor","volume":"49","author":"McCaw","year":"2003","journal-title":"Mol Microbiol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.6.3797","article-title":"The granulocyte receptor carcinoembryonic antigen-related cell adhesion molecule 3 (CEACAM3) directly associates with Vav to promote phagocytosis of human pathogens","volume":"178","author":"Schmitter","year":"2007","journal-title":"J Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2008.04.005","article-title":"CEACAM3: an innate immune receptor directed against human-restricted bacterial pathogens","volume":"298","author":"Pils","year":"2008","journal-title":"Int J Med Microbiol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-023-01516-3","article-title":"Development and characterization of NILK-2301, a novel CEACAM5xCD3 \u03ba\u03bb bispecific antibody for immunotherapy of CEACAM5-expressing cancers","volume":"16","author":"Seckinger","year":"2023","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1378813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T05:01:25Z","timestamp":1713934885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1378813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2024.1378813"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1378813","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"article-number":"1378813"}}